Golden
Editas Medicine

Editas Medicine

Editas Medicine is a genome editing company founded in 2013 that is using CRISPR technology to treat patients with genetically defined diseases.

Editas Medicine is a biotechnology and synthetic biology company using genetic engineering to create therapeutics for treating disease that is headquartered in Cambridge, Massachusetts and was founded in 2013 by Feng Zhang, J. Keith Joung, and Jennifer A. Doudna. 



Editas Medicine has developed a proprietary genome editing platform based on CRISPR using different engineered variants of CRISPR effector nucleases Cas9 and Cpf1 (also known as Cas12a). The company is working on editing efficiency, control of cutting and delivery of treatment to sight of disease. Editas Medicine is in the discovery stage of developing CRISPR gene edit treatments for the following conditions:



Leber Congenital Amaurosis 10 

Usher Syndrome 2a 

HSV-1 

T Cells for cancer treatments 

Beta Thalassemia 

Sickle Cell 

Cystic Fibrosis 

Alpha-I Antitrypsin Deficiency



Editas Medicine was previously founded under the name Gengine by Feng Zhang, George Church, Keith Joung, David Liu all from The Broad Institute at MIT and Harvard along with Jennifer Doudna from University of California, Berkeley. Jennifer Doudna left and co-founded Intellia Therapeutics. 



Timeline

People

Name
Role
Related Golden topics

Andrew Hack, M.D., Ph.D.

CFO



Charlene Stern, J.D., Ph.D.

Vice President and Head of Legal



Charles Albright, Ph.D.

CSO



Katrine Bosley

CEO



Semi Trotto

Vice President and Head of Human Resources



Timothy D. Hunt, J.D.

Senior Vice President of Corporate Affairs



Vic Myer, Ph.D.

Chief Technology Officer



Further reading

Title
Author
Link
Type
Date









Documentaries, videos and podcasts

Title
Date
Link





Companies

Company
CEO
Location
Products/Services









References